North America Intravenous Solutions Manufacturers Technological Advancements

Market Top Companies and Their Offerings

What are the Recent Developments in the Market?

• In September 2025, Eribulin Mesylate Injection was launched by Glenmark Pharmaceuticals Inc. in the U.S. market. The injection is bioequivalent and therapeutically equivalent to Eisai Inc.'s Halaven® Injection, which is an oncology drug for breast cancer, marking the company's entry into the complex generics arena.
• In May 2025, a new joint venture, Otsuka ICU Medical LLC., was formed by Otsuka Holdings Co., Ltd., the manufacturer and distributor of IV solutions, and ICU Medical Inc., a leader in the development, manufacture, and sale of innovative medical devices. The goal of this venture is to solidify the IV solutions supply chain resiliency and accelerate innovations across the North America Market.

Market Value Chain Analysis

R&D

• The R&D of the North America intravenous solutions focuses on the development of eco-friendly, non-PVC containers and automated multi-chamber nutritional bags.
• Key players: Baxter International Inc., B. Braun Medical Inc., ICU Medical, Inc.

Clinical Trials and Regulatory Approvals

• The sterility, ingredient purity, precise electrolyte osmolality safety, and container-fluid chemical compatibility are evaluated in the clinical trials and regulatory approvals of the intravenous solutions in North America.
• Key players: Baxter International Inc., B. Braun Medical Inc., ICU Medical, Inc.

Patient Support and Services

• Mobile home-infusion training application, 24/7 technical troubleshooting, and copay financial assistance programs are provided in the patient support and services of the intravenous solutions in North America.
• Key players: Baxter International Inc., B. Braun Medical Inc., ICU Medical, Inc.

Market Growth

The North America intravenous solutions market size was estimated at USD 5.84 billion in 2025 and is predicted to increase from USD 6.26 billion in 2026 to approximately USD 11.7 billion by 2035, expanding at a CAGR of 7.2% from 2026 to 2035.